Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 Par Value
-
Shares outstanding
-
27,913,938
-
Total 13F shares
-
13,034,173
-
Share change
-
-2,590,135
-
Total reported value
-
$56,047,183
-
Put/Call ratio
-
70%
-
Price per share
-
$4.30
-
Number of holders
-
66
-
Value change
-
-$70,633,595
-
Number of buys
-
29
-
Number of sells
-
51
Institutional Holders of Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) as of Q1 2025
As of 31 Mar 2025,
Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) was held by
66 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,034,173 shares.
The largest 10 holders included
Soleus Capital Management, L.P., Velan Capital Investment Management LP, Carlyle Group Inc., QIMING U.S. VENTURES MANAGEMENT, LLC, BlackRock, Inc., T. Rowe Price Investment Management, Inc., VANGUARD GROUP INC, MORGAN STANLEY, Integral Health Asset Management, LLC, and Rock Springs Capital Management LP.
This page lists
66
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.